External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology 2025 ASCO® Gastrointestinal Cancers Symposium
Roche and Genentech at

2025 ASCO® Gastrointestinal Cancers Symposium

January 23 - January 25
San Francisco, USA
conferences.asco.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Personalised Healthcare
Jan 24 / Roche and Genentech
Real-world (RW) experience with atezolizumab + bevacizumab (A+B) for the treatment of unresectable hepatocellular carcinoma (uHCC): A multicenter study
A+B is the preferred first-line (1L) standard of care for uHCC, with emerging Real World evidence supporting its use in a broad patient (pt) cohort. This poster reports on the evaluated pt characteristics, clinical and treatment outcomes in pts treated at five U.S. institutions: Mayo Clinic, Houston Methodist, Moffitt Cancer Center, Mays Cancer Center, and University of Arizona.
Oncology Gastric Cancer Gastrointestinal Cancer Real World Data - Real World Evidence ASCO-GI-2025

Sign up or login to unlock the full suite of MEDICALLY features
Jan 24 / Roche and Genentech
KIRROS: A phase II trial in progress of first-line atezolizumab (atezo) with or without bevacizumab (bev) in patients with unresectable hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis
This poster presents the background and study design for the prospective, open-label, multicohort, multicenter Phase II KIRROS trial, which will evaluate the safety and efficacy of first-line atezolizumab plus bevacizumab in participants with unresectable hepatocellular carcinoma (HCC) and Child-Pugh B cirrhosis.
Oncology Gastric Cancer Gastrointestinal Cancer ASCO-GI-2025
07:30 PM
Duration 90mins San Francisco, USA
KIRROS: A phase II trial in progress of first-line atezolizumab (atezo) with or without bevacizumab (bev) in patients with unresectable hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis
Kristen Spencer, Amit Singal, Laura Kulik, Augusto Villanueva, Renuka Iyer, Shilpa Chakalakal, Rucha Kothari, Jinnie Ko, Norelle Reilly, Thomas Stark, Anthony El-Khoueiry
Oncology | Gastric Cancer - Gastrointestinal Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins San Francisco, USA
Real-world (RW) experience with atezolizumab + bevacizumab (A+B) for the treatment of unresectable hepatocellular carcinoma (uHCC): A multicenter study
Maen Abdelrahim1, Abdullah Esmail1, Richard D. Kim2, Sukeshi Patel Arora3, Junaid Arshad4, Ioannis A. Kournoutas5, Conor D. O’Donnell5, Todor I. Totev6, Amie Tan7, Fan Mu6, Shravanthi M. Seshasayee6, Sairy Hernandez7, Nguyen H. Tran5
Oncology | Gastric Cancer - Gastrointestinal Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.